Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Zmień bibliotekę

Wyszukujesz frazę ""Kinase"" wg kryterium: Temat


Tytuł :
Design, synthesis and structure-activity relationship studies of pyrido[2,3-d]pyrimidin-7-ones as potent Janus Kinase 3 (JAK3) covalent inhibitors.
Autorzy :
Su W; Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China; Nano Science and Technology Institute, University of Science and Technology of China, Suzhou 215123, China.
Chen Z; International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MoE) of People's Republic of China, College of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China.
Liu M; Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
He R; International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MoE) of People's Republic of China, College of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China.
Liu C; Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
Li R; Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
Gao M; Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
Zheng M; Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
Tu Z; Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou Science Park, Guangzhou 510530, China.
Zhang Z; International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MoE) of People's Republic of China, College of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China. Electronic address: .
Xu T; Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China; School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China. Electronic address: .
Pokaż więcej
Źródło :
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2022 May 15; Vol. 64, pp. 128680. Date of Electronic Publication: 2022 Mar 16.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Janus Kinase 3*/metabolism
Protein Kinase Inhibitors*/pharmacology
Janus Kinase 1 ; Janus Kinase 2 ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes.
Autorzy :
Mascarenhas JO; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Verstovsek S; Leukemia Department, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
Pokaż więcej
Źródło :
Cancer [Cancer] 2022 Jul 15; Vol. 128 (14), pp. 2717-2727. Date of Electronic Publication: 2022 Apr 06.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Janus Kinase Inhibitors*/therapeutic use
Primary Myelofibrosis*/pathology
Animals ; Humans ; Janus Kinase 2 ; Mice ; Phosphatidylinositol 3-Kinases ; Protein Kinase Inhibitors/therapeutic use ; Proto-Oncogene Proteins c-bcl-2 ; Quality of Life
Czasopismo naukowe
Tytuł :
Cyclin-Dependent Kinase 4/6 Inhibitors: A Potential Breakthrough Therapy for Malignancies of Gastrointestinal Tract.
Autorzy :
Zeng F; Department of Thoracic Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, P.R. China.; Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, P.R. China.
Zhou Y; Department of Thoracic Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, P.R. China.; Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, P.R. China.
Khowtanapanich T; Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Saengboonmee C; Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand; .; Center for Translational Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.; Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen, Thailand.
Pokaż więcej
Źródło :
In vivo (Athens, Greece) [In Vivo] 2022 Jul-Aug; Vol. 36 (4), pp. 1580-1590.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Breast Neoplasms*/pathology
Cyclin-Dependent Kinase 6*/metabolism
Cyclin-Dependent Kinase 4/metabolism ; Cyclin-Dependent Kinase 4/therapeutic use ; Female ; Gastrointestinal Tract/pathology ; Humans ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
Mechanisms underlying melanoma invasion as a consequence of MLK3 loss.
Autorzy :
Balinda HU; Department of Biological Sciences, University of Notre Dame, Notre Dame, IN, 46556-0369, USA.
Sedgwick A; Department of Biological Sciences, University of Notre Dame, Notre Dame, IN, 46556-0369, USA.
D'Souza-Schorey C; Department of Biological Sciences, University of Notre Dame, Notre Dame, IN, 46556-0369, USA. Electronic address: .
Pokaż więcej
Źródło :
Experimental cell research [Exp Cell Res] 2022 Jun 01; Vol. 415 (1), pp. 113106. Date of Electronic Publication: 2022 Mar 18.
Typ publikacji :
Journal Article
MeSH Terms :
MAP Kinase Kinase Kinases*/metabolism
Melanoma*/genetics
Adaptor Proteins, Signal Transducing/metabolism ; Cell Line, Tumor ; HSP90 Heat-Shock Proteins/metabolism ; Humans ; MAP Kinase Signaling System ; Phosphorylation ; Proto-Oncogene Proteins B-raf/genetics ; Proto-Oncogene Proteins B-raf/metabolism
Czasopismo naukowe
Tytuł :
Targeting CDK4 and CDK6 in cancer.
Autorzy :
Goel S; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. .; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. .
Bergholz JS; Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Zhao JJ; Dana-Farber Cancer Institute, Boston, MA, USA. jean_.; Harvard Medical School, Boston, MA, USA. jean_.; Broad Institute of Harvard and MIT, Cambridge, MA, USA. jean_.
Pokaż więcej
Źródło :
Nature reviews. Cancer [Nat Rev Cancer] 2022 Jun; Vol. 22 (6), pp. 356-372. Date of Electronic Publication: 2022 Mar 18.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Breast Neoplasms*/metabolism
Protein Kinase Inhibitors*/pharmacology
Protein Kinase Inhibitors*/therapeutic use
Cell Cycle ; Cyclin-Dependent Kinase 4 ; Cyclin-Dependent Kinase 6 ; Female ; Humans
Czasopismo naukowe
Tytuł :
Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease.
Autorzy :
Nielsen OH; Department of Gastroenterology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark. Electronic address: .
Boye TL; Department of Gastroenterology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
Chakravarti D; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gubatan J; Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
Pokaż więcej
Źródło :
Trends in pharmacological sciences [Trends Pharmacol Sci] 2022 May; Vol. 43 (5), pp. 424-436. Date of Electronic Publication: 2022 Mar 08.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Biological Products*/therapeutic use
Inflammatory Bowel Diseases*/drug therapy
Janus Kinase Inhibitors*/pharmacology
Janus Kinase Inhibitors*/therapeutic use
Humans ; Janus Kinases ; TYK2 Kinase/therapeutic use
Czasopismo naukowe
Tytuł :
C5-Iminosugar modification of casein kinase 1δ lead 3-(4-fluorophenyl)-5-isopropyl-4-(pyridin-4-yl)isoxazole promotes enhanced inhibitor affinity and selectivity.
Autorzy :
von Drathen T; Ferrier Research Institute, Victoria University of Wellington, Lower Hutt, New Zealand.; Institute of Pharmacy, Christian-Albrechts-University of Kiel, Kiel, Germany.
Ure EM; Ferrier Research Institute, Victoria University of Wellington, Lower Hutt, New Zealand.
Kirschner S; Institute of Pharmacy, Christian-Albrechts-University of Kiel, Kiel, Germany.
Roth A; Department of General and Visceral Surgery, Ulm University Hospital, Ulm, Germany.
Meier L; Department of General and Visceral Surgery, Ulm University Hospital, Ulm, Germany.
Woolhouse AD; Ferrier Research Institute, Victoria University of Wellington, Lower Hutt, New Zealand.
Cameron SA; Ferrier Research Institute, Victoria University of Wellington, Lower Hutt, New Zealand.
Knippschild U; Department of General and Visceral Surgery, Ulm University Hospital, Ulm, Germany.
Peifer C; Institute of Pharmacy, Christian-Albrechts-University of Kiel, Kiel, Germany.
Luxenburger A; Ferrier Research Institute, Victoria University of Wellington, Lower Hutt, New Zealand.
Pokaż więcej
Źródło :
Archiv der Pharmazie [Arch Pharm (Weinheim)] 2022 May; Vol. 355 (5), pp. e2100497. Date of Electronic Publication: 2022 Feb 17.
Typ publikacji :
Journal Article
MeSH Terms :
Casein Kinase Idelta*/chemistry
Casein Kinase Idelta*/metabolism
Adenosine Triphosphate/metabolism ; Humans ; Isoxazoles/chemistry ; Isoxazoles/pharmacology ; Protein Kinase Inhibitors ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
Identification and Characterization of Natural and Semisynthetic Quinones as Aurora Kinase Inhibitors.
Autorzy :
Furqan M; Department of Biology, Syed Babar Ali School of Science and Engineering, Lahore University of Management Sciences, Lahore 54792, Pakistan.
Fayyaz A; Department of Biology, Syed Babar Ali School of Science and Engineering, Lahore University of Management Sciences, Lahore 54792, Pakistan.
Firdous F; Department of Biology, Syed Babar Ali School of Science and Engineering, Lahore University of Management Sciences, Lahore 54792, Pakistan.; Department of Chemistry and Chemical Engineering, Syed Babar Ali School of Science and Engineering, Lahore University of Management Sciences, Lahore 54792, Pakistan.
Raza H; Department of Biology, Syed Babar Ali School of Science and Engineering, Lahore University of Management Sciences, Lahore 54792, Pakistan.
Bilal A; Department of Biology, Syed Babar Ali School of Science and Engineering, Lahore University of Management Sciences, Lahore 54792, Pakistan.
Saleem RSZ; Department of Chemistry and Chemical Engineering, Syed Babar Ali School of Science and Engineering, Lahore University of Management Sciences, Lahore 54792, Pakistan.
Shahzad-Ul-Hussan S; Department of Biology, Syed Babar Ali School of Science and Engineering, Lahore University of Management Sciences, Lahore 54792, Pakistan.
Wang D; School of Pharmaceutical Sciences and Key Laboratory for Applied Technology of Sophisticated Analytical Instruments of Shandong Province, Shandong Analysis and Test Center, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250353, China.
Youssef FS; Department of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, Abbasia, Cairo 11566, Egypt.
Al Musayeib NM; Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Ashour ML; Department of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, Abbasia, Cairo 11566, Egypt.
Hussain H; Leibniz Institute of Plant Biochemistry, Department of Bioorganic Chemistry, Weinberg 3, D-06120 Halle (Saale), Germany.
Faisal A; Department of Biology, Syed Babar Ali School of Science and Engineering, Lahore University of Management Sciences, Lahore 54792, Pakistan.
Pokaż więcej
Źródło :
Journal of natural products [J Nat Prod] 2022 Jun 24; Vol. 85 (6), pp. 1503-1513. Date of Electronic Publication: 2022 Jun 10.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Aurora Kinase A*
Neoplasms*
Anthraquinones ; Aurora Kinase B ; DNA Helicases ; Humans ; Nuclear Proteins ; Protein Kinase Inhibitors/chemistry ; Protein Kinase Inhibitors/pharmacology ; Quinones/pharmacology ; Transcription Factors
Czasopismo naukowe
Tytuł :
Stabilization of CDK6 by ribosomal protein uS7, a target protein of the natural product fucoxanthinol.
Autorzy :
Iizumi Y; Department of Molecular-Targeting Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan. .
Sowa Y; Department of Molecular-Targeting Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
Goi W; Department of Molecular-Targeting Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
Aono Y; Department of Molecular-Targeting Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.; Department of Biomedical Chemistry, Graduate School of Science and Technology, Kwansei Gakuin University, 2-1 Gakuen, Sanda, Hyogo, 669-1337, Japan.
Watanabe M; Department of Molecular-Targeting Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
Kurumida Y; Artificial Intelligence Research Center, National Institute of Advanced Industrial Science and Technology (AIST), Tokyo, 135-0064, Japan.
Kameda T; Artificial Intelligence Research Center, National Institute of Advanced Industrial Science and Technology (AIST), Tokyo, 135-0064, Japan.
Akaji K; Department of Medicinal Chemistry, Kyoto Pharmaceutical University, Yamashina-ku, Kyoto, 607-8412, Japan.
Kitagawa M; Department of Molecular Biology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka, 431-3192, Japan.
Sakai T; Department of Molecular-Targeting Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.; Department of Drug Discovery Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
Pokaż więcej
Źródło :
Communications biology [Commun Biol] 2022 Jun 09; Vol. 5 (1), pp. 564. Date of Electronic Publication: 2022 Jun 09.
Typ publikacji :
Journal Article
MeSH Terms :
Biological Products*/pharmacology
Colonic Neoplasms*
Cyclin-Dependent Kinase 6*/genetics
Ribosomal Proteins*/genetics
beta Carotene*/analogs & derivatives
beta Carotene*/pharmacology
Cyclin-Dependent Kinase 2 ; Cyclin-Dependent Kinase 4 ; Cyclins/metabolism ; Humans
Czasopismo naukowe
Tytuł :
Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data.
Autorzy :
Martin JM; University Hospitals/Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Handorf EA; Fox Chase Cancer Center, Temple University, Philadelphia, PA, USA.
Montero AJ; University Hospitals/Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Goldstein LJ; Fox Chase Cancer Center, Temple University, Philadelphia, PA, USA.
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2022 Jun 08; Vol. 27 (6), pp. 441-446.
Typ publikacji :
Journal Article
MeSH Terms :
Breast Neoplasms*/drug therapy
Breast Neoplasms*/pathology
Protein Kinase Inhibitors*/therapeutic use
Antineoplastic Combined Chemotherapy Protocols ; Cyclin-Dependent Kinase 4 ; Cyclin-Dependent Kinase 6 ; Female ; Humans ; Prospective Studies ; Receptor, ErbB-2/metabolism
Czasopismo naukowe
Tytuł :
Functional Genomic Analysis of CDK4 and CDK6 Gene Dependency across Human Cancer Cell Lines.
Autorzy :
Zhang Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Cancer Program, Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Golomb L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Cancer Program, Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Meyerson M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Cancer Program, Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Department of Genetics, Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts.
Pokaż więcej
Źródło :
Cancer research [Cancer Res] 2022 Jun 06; Vol. 82 (11), pp. 2171-2184.
Typ publikacji :
Journal Article
MeSH Terms :
Breast Neoplasms*/genetics
Breast Neoplasms*/pathology
Protein Kinase Inhibitors*/pharmacology
Cell Line ; Cell Line, Tumor ; Cyclin-Dependent Kinase 4 ; Cyclin-Dependent Kinase 6 ; Female ; Genomics ; Humans
Czasopismo naukowe
Tytuł :
Momelotinib for the treatment of myelofibrosis with anemia.
Autorzy :
Tremblay D; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Mesa R; UT Health San Antonio Cancer Center, San Antonio, TX, USA.
Pokaż więcej
Źródło :
Future oncology (London, England) [Future Oncol] 2022 Jun; Vol. 18 (20), pp. 2559-2571. Date of Electronic Publication: 2022 May 23.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Anemia*/drug therapy
Anemia*/etiology
Janus Kinase Inhibitors*
Primary Myelofibrosis*/complications
Primary Myelofibrosis*/drug therapy
Primary Myelofibrosis*/metabolism
Benzamides/therapeutic use ; Humans ; Janus Kinase 2/genetics ; Nitriles/therapeutic use ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Pyrimidines ; Quality of Life
Czasopismo naukowe
Tytuł :
Aurora kinase a inhibitor MLN8237 suppresses pancreatic cancer growth.
Autorzy :
Zhang Y; Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.
Ma Y; Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA; Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Wang Y; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Mukhopadhyay D; Department of Biochemistry and Molecular Biology, Mayo Clinic, Jacksonville, FL, USA.
Bi Y; Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA.
Ji B; Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA. Electronic address: .
Pokaż więcej
Źródło :
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] [Pancreatology] 2022 Jun; Vol. 22 (5), pp. 619-625. Date of Electronic Publication: 2022 Apr 13.
Typ publikacji :
Journal Article
MeSH Terms :
Aurora Kinase A*/antagonists & inhibitors
Aurora Kinase A*/genetics
Aurora Kinase A*/metabolism
Azepines*/pharmacology
Carcinoma, Pancreatic Ductal*/drug therapy
Carcinoma, Pancreatic Ductal*/enzymology
Carcinoma, Pancreatic Ductal*/genetics
Carcinoma, Pancreatic Ductal*/pathology
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/enzymology
Pancreatic Neoplasms*/genetics
Pancreatic Neoplasms*/pathology
Pyrimidines*/pharmacology
Animals ; Apoptosis/drug effects ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Humans ; Mice ; Protein Kinase Inhibitors/pharmacology
SCR Disease Name :
Pancreatic Carcinoma
Czasopismo naukowe
Tytuł :
Circ_0085315 promotes cell proliferation, invasion, and migration in colon cancer through miR-1200/MAP3K1 signaling pathway.
Autorzy :
Luo Y; Department of Geriatrics, Ningbo First Hospital, Ningbo, Zhejiang Province, China.
Yao Q
Pokaż więcej
Źródło :
Cell cycle (Georgetown, Tex.) [Cell Cycle] 2022 Jun; Vol. 21 (11), pp. 1194-1211. Date of Electronic Publication: 2022 Mar 01.
Typ publikacji :
Journal Article
MeSH Terms :
Colonic Neoplasms*/genetics
Colonic Neoplasms*/metabolism
Colonic Neoplasms*/pathology
MAP Kinase Kinase Kinase 1*/genetics
MAP Kinase Kinase Kinase 1*/metabolism
MicroRNAs*/genetics
MicroRNAs*/metabolism
RNA, Circular*/genetics
RNA, Circular*/metabolism
Cell Line, Tumor ; Cell Proliferation/genetics ; Humans ; MAP Kinase Signaling System ; RNA, Messenger/genetics ; RNA, Messenger/metabolism ; Signal Transduction
Czasopismo naukowe
Tytuł :
Clinical and molecular correlates of JAK-inhibitor therapy failure in myelofibrosis: long-term data from a molecularly annotated cohort.
Autorzy :
England JT; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
McNamara CJ; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Kennedy JA; Medical Oncology and Hematology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Capo-Chichi JM; Division of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada.
Huang J; Biostatistics, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Arruda A; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Nye T; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Cheung V; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Claudio JO; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Maze D; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Sibai H; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Tierens A; Laboratory Hematology, Toronto General Hospital, Toronto, Ontario, Canada.
Tsui H; Laboratory Hematology, Toronto General Hospital, Toronto, Ontario, Canada.
Bankar A; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Xu W; Biostatistics, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Stockley T; Division of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada.; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Gupta V; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. .
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2022 Jun; Vol. 36 (6), pp. 1689-1692. Date of Electronic Publication: 2022 Mar 26.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Janus Kinase Inhibitors*/therapeutic use
Primary Myelofibrosis*/drug therapy
Primary Myelofibrosis*/genetics
Cohort Studies ; Humans ; Janus Kinase 2/genetics ; Janus Kinases ; Nitriles/therapeutic use ; Protein Kinase Inhibitors/therapeutic use
Raport
Tytuł :
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3 -ITD acute myeloid leukemia.
Autorzy :
Post SM; Department of Leukemia. .
Ma H; Department of Leukemia; Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston.
Malaney P; Department of Leukemia.
Zhang X; Department of Leukemia.
Aitken MJL; Department of Leukemia.
Mak PY; Department of Leukemia; Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston.
Ruvolo VR; Department of Leukemia; Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston.
Yasuhiro T; Ono Pharmaceutical Co. Ltd., Research Center of Oncology, Osaka.
Kozaki R; Ono Pharmaceutical Co. Ltd., Research Center of Oncology, Osaka.
Chan LE; Department of Leukemia.
Ostermann LB; Department of Leukemia; Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston.
Konopleva M; Department of Leukemia.
Carter BZ; Department of Leukemia; Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston.
DiNardo C; Department of Leukemia.
Andreeff MD; Department of Leukemia; Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston.
Khoury JD; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston. .
Ruvolo PP; Department of Leukemia; Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston. .
Pokaż więcej
Źródło :
Haematologica [Haematologica] 2022 Jun 01; Vol. 107 (6), pp. 1311-1322. Date of Electronic Publication: 2022 Jun 01.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Resistance, Neoplasm*
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Protein Kinase Inhibitors*/pharmacology
c-Mer Tyrosine Kinase*/antagonists & inhibitors
Animals ; Apoptosis ; Bridged Bicyclo Compounds, Heterocyclic/pharmacology ; Cell Line, Tumor ; Extracellular Signal-Regulated MAP Kinases/metabolism ; Humans ; Mice ; Myeloid Cell Leukemia Sequence 1 Protein/metabolism ; Proteomics ; Sulfonamides/pharmacology ; fms-Like Tyrosine Kinase 3/genetics
Czasopismo naukowe
Tytuł :
A computationally affordable approach for accurate prediction of the binding affinity of JAK2 inhibitors.
Autorzy :
Mai NT; Institute of Materials Science, Vietnam Academy of Science and Technology, Hanoi, Vietnam.; Graduate University of Science and Technology, Vietnam Academy of Science and Technology, Hanoi, Vietnam.
Lan NT; Graduate University of Science and Technology, Vietnam Academy of Science and Technology, Hanoi, Vietnam.; Institute of Science and Technology, TNU-University of Sciences, Thai Nguyen, Tan Thinh, Vietnam.
Vu TY; Faculty of Pharmacy, Ton Duc Thang University, Ho Chi Minh City, Vietnam.
Tung NT; Institute of Materials Science, Vietnam Academy of Science and Technology, Hanoi, Vietnam. .; Graduate University of Science and Technology, Vietnam Academy of Science and Technology, Hanoi, Vietnam. .
Phung HTT; NTT Hi-Tech Institute, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam. .
Pokaż więcej
Źródło :
Journal of molecular modeling [J Mol Model] 2022 May 23; Vol. 28 (6), pp. 163. Date of Electronic Publication: 2022 May 23.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents*
Janus Kinase Inhibitors*
Janus Kinase 2/chemistry ; Janus Kinase 2/metabolism ; Janus Kinases ; Ligands ; Protein Kinase Inhibitors/chemistry
Czasopismo naukowe
Tytuł :
Aberrant Activation of Cell-Cycle-Related Kinases and the Potential Therapeutic Impact of PLK1 or CHEK1 Inhibition in Uterine Leiomyosarcoma.
Autorzy :
Yoshida K; Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.; Institute for Advanced Research, Nagoya University, Nagoya, Japan.; Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Yokoi A; Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.; Institute for Advanced Research, Nagoya University, Nagoya, Japan.
Yamamoto T; Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Hayashi Y; Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Nakayama J; Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Yokoi T; Division of Clinical Pharmacology, Department of Drug Safety Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yoshida H; Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
Kato T; Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan.
Kajiyama H; Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yamamoto Y; Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Pokaż więcej
Źródło :
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 May 13; Vol. 28 (10), pp. 2147-2159.
Typ publikacji :
Journal Article
MeSH Terms :
Cell Cycle Proteins*/antagonists & inhibitors
Cell Cycle Proteins*/genetics
Checkpoint Kinase 1*/antagonists & inhibitors
Checkpoint Kinase 1*/genetics
Leiomyosarcoma*/drug therapy
Leiomyosarcoma*/genetics
Leiomyosarcoma*/metabolism
Protein Serine-Threonine Kinases*/antagonists & inhibitors
Protein Serine-Threonine Kinases*/genetics
Proto-Oncogene Proteins*/antagonists & inhibitors
Proto-Oncogene Proteins*/genetics
Uterine Neoplasms*/drug therapy
Uterine Neoplasms*/genetics
Uterine Neoplasms*/metabolism
Animals ; Cell Cycle Checkpoints ; Cell Line, Tumor ; Cisplatin/therapeutic use ; Female ; Humans ; Mice ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Tytuł :
Small-molecule IKKβ activation modulator (IKAM) targets MAP3K1 and inhibits pancreatic tumor growth.
Autorzy :
Napoleon JV; Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68198.
Sagar S; Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68198.
Kubica SP; Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68198.
Boghean L; Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68198.
Kour S; Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68198.
King HM; Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68198.
Sonawane YA; Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68198.
Crawford AJ; Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68198.
Gautam N; Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198.
Kizhake S; Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68198.
Bialk PA; Gene Editing Institute, Christiana Care, Newark, DE 19713.
Kmiec E; Gene Editing Institute, Christiana Care, Newark, DE 19713.
Mallareddy JR; Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68198.
Patil PP; Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68198.
Rana S; Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68198.
Singh S; Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68198.
Prahlad J; Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68198.
Grandgenett PM; Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68198.
Borgstahl GEO; Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68198.
Ghosal G; Department of Genetics Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE 68198.
Alnouti Y; Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198.
Hollingsworth MA; Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68198.; Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198.
Radhakrishnan P; Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68198.; Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198.
Natarajan A; Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68198.; Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198.; Department of Genetics Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE 68198.; Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198.
Pokaż więcej
Źródło :
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2022 May 03; Vol. 119 (18), pp. e2115071119. Date of Electronic Publication: 2022 Apr 27.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
MAP Kinase Kinase Kinase 1*
Pancreatic Neoplasms*/drug therapy
Humans ; I-kappa B Kinase/metabolism ; Protein Serine-Threonine Kinases
SCR Disease Name :
Pancreatic Carcinoma
Czasopismo naukowe
Tytuł :
Gamma synuclein promotes cancer metastasis through the MKK3/6-p38MAPK cascade.
Autorzy :
Liu J; Laboratory of Oncogene, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Shao T; Laboratory of Oncogene, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.; Current address: BeiGene (Shanghai) Co., Ltd, Shanghai, China.
Zhang J; Laboratory of Oncogene, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Liu Q; Laboratory of Oncogene, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Hua H; Laboratory of Stem Cell Biology, West China Hospital, Sichuan University. Chengdu, China.
Zhang H; Laboratory of Oncogene, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Wang J; School of Basic Medicine, Chengdu University of Traditional Chinese Medicine. Chengdu, China.
Luo T; Cancer center, West China Hospital, Sichuan University. Chengdu, China.
Shi YE; Chimigen Bio, Chengdu, China.
Jiang Y; Laboratory of Oncogene, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Pokaż więcej
Źródło :
International journal of biological sciences [Int J Biol Sci] 2022 May 01; Vol. 18 (8), pp. 3167-3177. Date of Electronic Publication: 2022 May 01 (Print Publication: 2022).
Typ publikacji :
Journal Article
MeSH Terms :
MAP Kinase Signaling System*/genetics
Neoplasm Metastasis*
gamma-Synuclein*/genetics
gamma-Synuclein*/metabolism
Humans ; MAP Kinase Kinase 3 ; MAP Kinase Kinase 6 ; Neoplasm Invasiveness ; Neoplasm Proteins ; Transforming Growth Factor beta/metabolism ; p38 Mitogen-Activated Protein Kinases/metabolism
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies